Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Latest From Mytogen

Stem Cell Therapies: Excitement Builds but Challenges Remain

With weak pharmaceutical pipelines and demand increasing for tailored medical approaches, adult and embryonic stem cell therapies are gaining ground as a therapeutic focus. Numerous companies are now active in this research and some observers estimate that the stem cell market could reach between $8.5 and $10 billion within the next ten years.


ACC Highlights: Better Stents, But Are Stents Often Necessary?

The 56th Annual American College of Cardiology conference provided the expected clinical trial updates on a variety of interventional devices. But the most anticipated and surprising news of the meeting came from the COURAGE study, whose results broke against the tide of using interventional procedures and stents as primary therapy for stable coronary artery disease.

BioPharmaceutical Medical Device

Succeeding in Heart Failure, Incrementally

Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.

BioPharmaceutical Strategy

Biotechnology North of the Border

A venture-backed Canadian biotechnology industry is in its infancy, but faced with hostile capital markets, start-ups need clear exit plans. Consolidation's already started.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy